Previous 10 | Next 10 |
ESSA Pharma to Participate in Oppenheimer Fall Healthcare Life Science & MedTech Summit ESSA Pharma to Participate in Oppenheimer Fall Healthcare Life Science & MedTech Summit PR Newswire HOUSTON and VANCOUVER, BC, Sept. 21, 2020 HOUSTON and VANCOUV...
ESSA Pharma Announces the Presentation of Additional Preclinical Data for EPI-7386 at the ESMO Virtual Congress 2020 Canada NewsWire HOUSTON and VANCOUVER, BC, Sept. 17, 2020 HOUSTON and VANCOUVER, BC , Sept. 17, 2020 /CNW/ - ESSA Pharma Inc. (Nasdaq: EPIX) (TSX-V: EPI)...
The FDA has designated ESSA Pharma' (NASDAQ: EPIX ) EPI-7386 for Fast Track review for the treatment of metastatic castration-resistant prostate cancer (mCRPC), resistant to standard-of-care treatment. More news on: ESSA Pharma Inc., Healthcare stocks news, ...
HOUSTON and VANCOUVER, BC , Sept. 14, 2020 /PRNewswire/ - ESSA Pharma Inc. (NASDAQ: EPIX) (TSXV: EPI) ("ESSA" or the "Company"), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer today announced that the U.S. Food a...
HOUSTON and VANCOUVER, BC , Sept. 10, 2020 /PRNewswire/ - ESSA Pharma Inc. (Nasdaq: EPIX; TSX-V: EPI; ) ("ESSA" or the "Company"), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer announced the Company will be presentin...
ESSA Pharma Inc. (NASDAQ: EPIX ) [TSX-V: EPI] is a Canadian/U.S. clinical-stage pharmaceutical company which recently began Phase 1 clinical trials for its lead drug EPI-7386, a novel treatment for men with castration-resistant prostate cancer ("CRPC") where the cancer is progressing despi...
ESSA Pharma (NASDAQ: EPIX ) : Q3 GAAP EPS of -$0.24 beats by $0.06 . More news on: ESSA Pharma Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Third Quarter Ended June 30, 2020 Canada NewsWire VANCOUVER, BC and HOUSTON, Aug. 6, 2020 VANCOUVER, BC and HOUSTON , Aug. 6, 2020 /CNW/ - ESSA Pharma Inc. ("ESSA", or the "Company") (...
ESSA Pharma ( EPIX -1.5% ) announces the closing of an underwritten public offering of 7,100,000 shares at a price of $6 per share. More news on: ESSA Pharma Inc., Read more ...
ESSA Pharma Completes Public Offering for Aggregate Gross Proceeds of US$48,990,000 Canada NewsWire HOUSTON and VANCOUVER, BC, July 31, 2020 HOUSTON and VANCOUVER, BC , July 31, 2020 /CNW/ - ESSA Pharma Inc. ("ESSA", or the "Company") (Nasdaq: EPIX) (TSX-V: EPI), a...
News, Short Squeeze, Breakout and More Instantly...
ESSA Pharma to Present at the JonesHealthcare Seaside Summit Canada NewsWire SOUTH SAN FRANCISCO, Calif. and VANCOUVER, BC , July 8, 2024 /CNW/ - ESSA Pharma Inc. ("ESSA," or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on de...
ESSA Pharma to Present at the Jefferies Global Healthcare Conference Canada NewsWire SOUTH SAN FRANCISCO, Calif. and VANCOUVER, BC , May 30, 2024 /CNW/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focus...